Phaseline

Targets › TNFRSF13C

TNFRSF13C (Tumor necrosis factor receptor superfamily member 13C): drug programs, companies and trials

6 programs from 6 companies in 22 trials: 11 Phase 3, 6 Phase 1, 5 Phase 2; Oncology, Hematology, Immunology; next expected readout Nov 2026.

B-cell receptor specific for TNFSF13B/TALL1/BAFF/BLyS. Promotes the survival of mature B-cells and the B-cell response. (UniProt, Q96RJ3)

Open in Phaseline: the race on TNFRSF13C, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisIanalumab (VAY736)
Tumor necrosis factor receptor superfamily member 13C binding agent
TNFRSF13CPhase 3Systemic Lupus Erythematosus; Sjogren Syndrome; Lupus Nephritis; Primary Immune Thrombocytopenia …Mar 2027
PeproMene BioBAFFR-CAR T cells
BAFFR-targeting CAR T cell therapy
TNFRSF13CPhase 1Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed or Refractory B-cell Non-Hodgkin's LymphomaNov 2026
Jiangsu Topcel-KH PharmaceuticalBAFF-R CAR-T cells
BAFF receptor-targeted chimeric antigen receptor T-cell therapy
TNFRSF13CPhase 1B-cell LymphomaJan 2027
Tianjin Medical University General HospitalBAFF-R CART
CAR-T cell therapy targeting BAFF receptor
TNFRSF13CPhase 1Chronic Inflammatory Demyelinating PolyradiculoneuropathyDec 2027
Paolo Caimi, MDBAFF CAR-T (LMY-920)
CAR-T cells expressing B-cell activating factor (BAFF) ligand targeting BAFF receptor
TNFRSF13CPhase 1Relapsed CLLDec 2027
Institute of Hematology & Blood Diseases Hospital, ChinaBAFF-R CAR-T
BAFF-R-targeted chimeric antigen receptor T-cell therapy
TNFRSF13CPhase 1DLBCLNov 2029

Conditions

Systemic Lupus Erythematosus (3) Primary Immune Thrombocytopenia (ITP) (3) Lupus Nephritis (2) Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (1) Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (1) Sjogren Syndrome (1) Primary Immune Thrombocytopenia (1) Warm Autoimmune Hemolytic Anemia (wAIHA) (1) Sjögren´s Disease (1) Sjogrens Syndrome (1) Hidradenitis Suppurativa (1) Diffuse Cutaneous Systemic Sclerosis (1)

Modalities

other (4), antibody (1), mixed (1)

Companies

PeproMene Bio (1) Novartis (1) Paolo Caimi, MD (1) Tianjin Medical University General Hospital (1) Jiangsu Topcel-KH Pharmaceutical (1) Institute of Hematology & Blood Diseases Hospital, China (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.